HIV-1 resistance testing influences treatment decision-making

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 5, 2010, Pages 489-494

  Diaz, Ricardo Sobhie ^a   Sucupira, Maria Cecilia A ^a   Vergara, Tania R C ^a   Brites, Carlos ^b   Del Bianco, Rosana ^c   Filho, Francisco Bonasser ^c   Colares, Geova Keny B ^d   Portela, Estevão ^e   Cherman, Lia Adler ^f   Barcelos, Nemora Tregnago ^g   Tupinambas, Unai ^h   Turcato Jr , Gilberto ^a   Allamasey, Lisa ⁱ   Bacheler, Lee ^j   Tuohy, Martin ⁱ  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c Hospital Emilio Ribas   (Brazil)

^d UNIVERSITY OF FORTALEZA   (Brazil)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f Network Reference Physicians Working Group   (Brazil)

^g Instituto Federal do Rio Grande do Sul   (Brazil)

^h FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

ⁱ Virco BVBA   (Belgium)

^j VircoLab Inc   (United States)

more..

Author keywords

Antiretroviral resistance; Brazil; Genotype; Virtual phenotype

Indexed keywords

3' O BENZYLTRIFLURIDINE; ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BRAZIL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DECISION MAKING; DRUG COST; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHENOTYPE; PHYSICIAN ATTITUDE; SALVAGE THERAPY; TREATMENT PLANNING; VIRUS RESISTANCE;

EID: 78951471112     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1413-8670(10)70098-2     Document Type: Article

References (16)

1. Deeks SG, Hoh R, Neilands TB et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug- resistant HIV-1 infection. J Infect Dis 2005; 192:1537-44.
2. Medeiros R, Diaz RS, Filho AC. Estimating the length of the first antiretroviral therapy regimen durability in São Paulo, Brazil. Braz J Infect Dis 2002; 6:298-304.
3. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron Jr JJ. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005; 40:34-40.
4. Sucupira MC, Souza IE, Costa LJ, Scheinberg MA, Diaz RS. Antiretroviral treatment failure and HIV-1 genotypic resistance in São Paulo, Brazil. Antivir Ther 2001; 6:263-4.
5. Lohse N, Kronborg G, Gerstoft J et al. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. Clin Infect Dis 2006; 42:136-44.
6. Zaccarelli M, Tozzi V, Lorenzini P et al. Multiple drug classwide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. Aids 2005; 19:1081-9.
7. Durant J, Clevenbergh P, Halfon P et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-9.
8. Baxter JD, Mayers DL, Wentworth DN et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. Aids 2000; 14:F83-93.
9. Cohen CJ, Hunt S, Sension M et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. Aids 2002; 16:579-88.
10. Tural C, Ruiz L, Holtzer C et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. Aids 2002; 16:209-18.
11. Vray M, Meynard JL, Dalban C et al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther 2003; 8:427-34.
12. Mazzotta F, Lo Caputo S, Torti C et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr 2003; 32:268-80.
13. Perez-Elias MJ, Garcia-Arota I, Munoz V et al. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antivir Ther 2003; 8:577-84.
14. Swanstrom R, Bosch RJ, Katzenstein D et al. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis 2004; 190:886-93.
15. Weinstein MC, Goldie SJ, Losina E et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134:440-50.
16. th Conference on Retroviruses and Opportunistic Infections. Denver, CO, 5-8 February 2006.